Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 5c; Reports Cash and Cash Equivalents of $28M

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Wealthfront launches custodial account with tax-gain harvesting
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks